Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;5(23):474.
doi: 10.21037/atm.2017.10.11.

Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world

Richard J MacIsaac  1   2 , Elif I Ekinci  3   4
Affiliations
Editorial

Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world

Richard J MacIsaac et al. Ann Transl Med. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Professor RJ MacIsaac has received honoraria for lectures and travel support from Eli lily, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp & Dohme, Boehringer Ingelheim and Norvartis. He has also received research grants from Novo Nordisk and Servier in the past and is currently on advisory boards for Novo Nordisk, the Astra-Zeneca & Bristol Myers Diabetes Alliance and the Boehringer Ingelheim & Lilly Diabetes Alliance. He was an investigator on the CANVAS-R trial involving canagliflozin. Dr. EI Ekinci was supported by a Viertel Clinical Investigatorship, RACP Fellowship, a Diabetes Australia Research Program Grant and Sir Edward Weary Dunlop Medical Research Foundation research grant.

Comment on

References

    1. Emerging Risk Factors Collaboration , Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22. 10.1016/S0140-6736(10)60484-9 - DOI - PMC - PubMed
    1. McMurray JJ, Gerstein HC, Holman RR, et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-51. 10.1016/S2213-8587(14)70031-2 - DOI - PubMed
    1. Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703. 10.2337/diacare.27.3.699 - DOI - PubMed
    1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28. 10.1056/NEJMoa1504720 - DOI - PubMed
    1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. 10.1056/NEJMoa1611925 - DOI - PubMed

LinkOut - more resources